Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 25-36 of 77 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 25-36 of 77 studies
-
Restore CFTR ProteinCompleted with Results
Roll-over study of ivacaftor in children with CF who have a CFTR gating mutation , protocol number Vertex VX-770-109This study evaluated the long-term safety of ivacaftor (Kalydeco®) in children with CF. This study was for children who have a CFTR gating mutation and received at least one dose of ivacaftor in the VX11-770-108 study.
-
Age:
2 Years to 5 Years
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
7
-
Length of Participation:
88 weeks
-
-
Restore CFTR ProteinCompleted with Results
Open-label study of ivacaftor in people with CF who have a non-G551D CFTR gating mutation , protocol number Vertex VX-770-112This study evaluated the long-term safety of ivacaftor (Kalydeco®) in participants who have a non-G551D CFTR gating mutation. This study was for people who had participated in one of the VX11-770-110, VX12-770-111, or VX12-770-113 studies.
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
7
-
Length of Participation:
2 years
-
-
Restore CFTR ProteinCompleted with Results
Phase 2 study of PTI-808 triple-combination therapy in adults with cystic fibrosis who have at least one copy of the F508del mutation , protocol number PTI-808-01This study evaluated the effectiveness and safety of the drug, PTI-808 in combination with PTI-801, with or without PTI-428. This study was for people with CF ages 18 and older who have at least one copy of the F508del CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
9
-
Length of Participation:
10 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study to evaluate VX-121 in adults 18 years and older with cystic fibrosis , protocol number Vx-121-101 (VX18-121-101)This study evaluated the safety, tolerability, and effectiveness of three different doses of the drug VX-121 in triple combination with tezacaftor (TEZ) and VX-561 (deuterated ivacaftor) in people with cystic fibrosis who have two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
17 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study to evaluate VX-561 in adults 18 years and older with cystic fibrosis , protocol number Vertex VX-561-101This study evaluated different doses of the drug VX-561 to determine safety and effectiveness.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
8
-
Length of Participation:
16 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of ivacaftor in babies 12-24 month old who have a CFTR gating mutation , protocol number Vertex VX15-770-124This study evaluated the safety of ivacaftor (Kalydeco®) as well as how the body processes the drug in babies who have at least one copy of a CFTR gating mutation.
-
Age:
12 Months to 24 Months
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
24 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 2 study of PTI-428 drug in people with CF ages 18 and older who have two copies of the F508del CFTR mutation , protocol number Proteostasis PTI-428-06This study evaluated the safety and tolerability of the drug PTI-428. This study was for people with CF ages 18 and older who have two copies of the F508del CFTR mutation and were already taking tezacaftor/ivacaftor (Symdeko®). A key goal of the study was to determine if PTI-428 could increase the amount of CFTR protein produced in people who were already taking tezacaftor/ivacaftor (Symdeko®).
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
74 days
-
-
Restore CFTR ProteinCompleted with Results
Study of VX-445 plus ivacaftor and tezacaftor in people with CF who have two copies of the F508del CFTR mutation , protocol number Vertex VX17-445-103This study evaluated the effectiveness and safety of the CFTR modulator drug VX-445 (elexacaftor) in combination with ivacaftor and tezacaftor. This triple combination is known as Trikafta™. This study was for people with CF ages 12 and older who have two copies of the F508del CFTR mutation and were already taking tezacaftor plus ivacaftor.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
10 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study of effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in people with CF who have one copy of the F508del CFTR mutation , protocol number Vertex VX17-445-102This study evaluated the effectiveness and safety of the CFTR modulator drug VX-445 (elexacaftor) in combination with tezacaftor and ivacaftor (ELX/TEZ/IVA). This triple combination drug is known as Trikafta™. This study was for people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of VX-659 triple combination drug in people with CF ages 12 years and older who have two copies of the F508del mutation , protocol number VX17-659-103This study evaluated the safety and effectiveness of the drug VX-659 in combination with tezacaftor and ivacaftor in people with cystic fibrosis ages 12 and older with two copies of the F508del CFTR mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
10 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of VX-659 triple combination drug in people with CF 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation , protocol number VX17-659-102This study evaluated the safety and effectiveness of the drug VX-659 in combination with tezacaftor and ivacaftor in people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinCompleted with Results
A study to evaluate tezacaftor/ivacaftor in adults with cystic fibrosis and two copies of the F508del mutation , protocol number Vertex VX16-661-114This study evaluated the safety, effectiveness, and tolerability of the drug tezacaftor/ivacaftor (Symdeko®). This study was for people with CF ages 12 and older with two copies of the F508del CFTR mutation who had been taken off lumacaftor/ivacaftor (Orkambi®) due to respiratory side effects.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
25 to 90%
-
Number of Visits:
5
-
Length of Participation:
84 days
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More